Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Brain Cancer

Brain Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Brain Cancer

245 trials tracked for Brain Cancer: 19 in phase 3 or 4 and 7 with published results. The most-cited published study has 1171 citations.

245Trials tracked
19Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 6 Phase 3 13 Phase 2 178 Phase 1 21 Other / NA 27
  1. Phase 3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed · 1,171 cited
  2. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 490 cited
  3. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 474 cited
  4. Phase 3 Preoperative Alpha Blockade for Pheochromocytoma Completed · 183 cited
  5. Phase 3 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed · 26 cited
  6. Phase 3 Hypovitaminosis D in Neurocritical Patients Completed · 21 cited
Show 44 more trials
  1. Phase 4 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Completed
  2. Phase 4 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed
  3. Phase 4 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed
  4. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  5. Phase 4 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Completed
  6. Phase 4 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed
  7. Phase 3 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed
  8. Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
  9. Phase 3 Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas Completed
  10. Phase 3 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed
  11. Phase 3 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed
  12. Phase 3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed
  13. Phase 3 Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy Completed
  14. Phase 2 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed
  15. Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
  16. Phase 2 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Completed
  17. Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide Completed
  18. Phase 2 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Completed
  19. Phase 2 Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. Completed
  20. Phase 2 Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas Completed
  21. Phase 2 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed
  22. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  23. Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
  24. Phase 2 Low Dose Naltrexone for Glioma Patients Completed
  25. Phase 2 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed
  26. Phase 2 LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed
  27. Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
  28. Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Completed
  29. Phase 2 Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed
  30. Phase 2 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Completed
  31. Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed
  32. Phase 2 Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
  33. Phase 2 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors Completed
  34. Phase 2 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Completed
  35. Phase 2 Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
  36. Phase 2 Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Completed
  37. Phase 2 MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma Completed
  38. Phase 2 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Completed
  39. Phase 2 Study of MEK162 for Children With Low-Grade Gliomas Completed
  40. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  41. Phase 2 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Completed
  42. Phase 2 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma Completed
  43. Phase 2 Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas Completed
  44. Phase 2 PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Completed

Showing the 50 most-cited and recently-updated of 245 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.